Mechanism of Interleukin-1β induced-increase in mouse intestinal permeability in vivo

Rana Al-Sadi, Shuhong Guo, Karol Dokladny, Matthew A. Smith, Dongmei Ye, Archana Kaza, D. Martin Watterson, Thomas Ma

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Interleukin-1β (IL-1β) has been shown to play an essential role in mediating intestinal inflammation of Crohn's disease and other inflammatory conditions of the gut. Previous studies from our laboratory have shown that IL-1β causes an increase in intestinal tight-junction permeability in Caco-2 monolayers in vitro. However, the IL-1β effect on the intestinal epithelial barrier in vivo remains unclear. Aims: the major aims of this study were to examine the effect of IL-1β on mouse intestinal epithelial barrier in vivo and to delineate the mechanisms involved using an in vivo model system consisting of a recycling perfusion of mouse small intestine. Intraperitonial injection of IL-1β at varying doses (0-10μg) caused a concentration-dependent increase in mouse intestinal permeability to the paracellular marker dextran (10 KD), and the maximal increase in dextran flux occurred at IL-1β dose of 5μg. IL-1β treatment caused an increase in myosin light-chain kinase (MLCK) mRNA and protein expression in the small intestinal tissue starting at 24h, which continued up to 72h. Additionally, IL-1β did not cause an increase in intestinal permeability in MLCK-deficient mice (C57BL/6 MLCK-/-). MLCK inhibitor ML-7 (2mg/kg body weight) also inhibited the IL-1β-induced increase in small intestinal permeability. The IL-1β-induced increase in mouse intestinal permeability was associated with an increase in NF-κB activation. The intestinal tissue-specific silencing of NF-κB p65 inhibited the IL-1β-induced increase in intestinal permeability and increase in MLCK expression. These data show for the first time that IL-1β causes an increase in mouse intestinal permeability in vivo. These data suggested that the mechanism of IL-1β-induced increase in mouse intestinal permeability in vivo involved NF-κB p65-induced activation of the mouse enterocyte MLCK gene.

Original languageEnglish (US)
Pages (from-to)474-484
Number of pages11
JournalJournal of Interferon and Cytokine Research
Volume32
Issue number10
DOIs
StatePublished - Oct 1 2012

Fingerprint

Interleukin-1
Permeability
Myosin-Light-Chain Kinase
Dextrans
Enterocytes
Tight Junctions
Recycling
Inbred C57BL Mouse
Crohn Disease
Small Intestine
Perfusion
Body Weight
Inflammation

All Science Journal Classification (ASJC) codes

  • Immunology
  • Cell Biology
  • Virology

Cite this

Al-Sadi, Rana ; Guo, Shuhong ; Dokladny, Karol ; Smith, Matthew A. ; Ye, Dongmei ; Kaza, Archana ; Watterson, D. Martin ; Ma, Thomas. / Mechanism of Interleukin-1β induced-increase in mouse intestinal permeability in vivo. In: Journal of Interferon and Cytokine Research. 2012 ; Vol. 32, No. 10. pp. 474-484.
@article{8d58bfd51a8f4543a1f861eee1979f7d,
title = "Mechanism of Interleukin-1β induced-increase in mouse intestinal permeability in vivo",
abstract = "Interleukin-1β (IL-1β) has been shown to play an essential role in mediating intestinal inflammation of Crohn's disease and other inflammatory conditions of the gut. Previous studies from our laboratory have shown that IL-1β causes an increase in intestinal tight-junction permeability in Caco-2 monolayers in vitro. However, the IL-1β effect on the intestinal epithelial barrier in vivo remains unclear. Aims: the major aims of this study were to examine the effect of IL-1β on mouse intestinal epithelial barrier in vivo and to delineate the mechanisms involved using an in vivo model system consisting of a recycling perfusion of mouse small intestine. Intraperitonial injection of IL-1β at varying doses (0-10μg) caused a concentration-dependent increase in mouse intestinal permeability to the paracellular marker dextran (10 KD), and the maximal increase in dextran flux occurred at IL-1β dose of 5μg. IL-1β treatment caused an increase in myosin light-chain kinase (MLCK) mRNA and protein expression in the small intestinal tissue starting at 24h, which continued up to 72h. Additionally, IL-1β did not cause an increase in intestinal permeability in MLCK-deficient mice (C57BL/6 MLCK-/-). MLCK inhibitor ML-7 (2mg/kg body weight) also inhibited the IL-1β-induced increase in small intestinal permeability. The IL-1β-induced increase in mouse intestinal permeability was associated with an increase in NF-κB activation. The intestinal tissue-specific silencing of NF-κB p65 inhibited the IL-1β-induced increase in intestinal permeability and increase in MLCK expression. These data show for the first time that IL-1β causes an increase in mouse intestinal permeability in vivo. These data suggested that the mechanism of IL-1β-induced increase in mouse intestinal permeability in vivo involved NF-κB p65-induced activation of the mouse enterocyte MLCK gene.",
author = "Rana Al-Sadi and Shuhong Guo and Karol Dokladny and Smith, {Matthew A.} and Dongmei Ye and Archana Kaza and Watterson, {D. Martin} and Thomas Ma",
year = "2012",
month = "10",
day = "1",
doi = "10.1089/jir.2012.0031",
language = "English (US)",
volume = "32",
pages = "474--484",
journal = "Journal of Interferon and Cytokine Research",
issn = "1079-9907",
publisher = "Mary Ann Liebert Inc.",
number = "10",

}

Mechanism of Interleukin-1β induced-increase in mouse intestinal permeability in vivo. / Al-Sadi, Rana; Guo, Shuhong; Dokladny, Karol; Smith, Matthew A.; Ye, Dongmei; Kaza, Archana; Watterson, D. Martin; Ma, Thomas.

In: Journal of Interferon and Cytokine Research, Vol. 32, No. 10, 01.10.2012, p. 474-484.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Mechanism of Interleukin-1β induced-increase in mouse intestinal permeability in vivo

AU - Al-Sadi, Rana

AU - Guo, Shuhong

AU - Dokladny, Karol

AU - Smith, Matthew A.

AU - Ye, Dongmei

AU - Kaza, Archana

AU - Watterson, D. Martin

AU - Ma, Thomas

PY - 2012/10/1

Y1 - 2012/10/1

N2 - Interleukin-1β (IL-1β) has been shown to play an essential role in mediating intestinal inflammation of Crohn's disease and other inflammatory conditions of the gut. Previous studies from our laboratory have shown that IL-1β causes an increase in intestinal tight-junction permeability in Caco-2 monolayers in vitro. However, the IL-1β effect on the intestinal epithelial barrier in vivo remains unclear. Aims: the major aims of this study were to examine the effect of IL-1β on mouse intestinal epithelial barrier in vivo and to delineate the mechanisms involved using an in vivo model system consisting of a recycling perfusion of mouse small intestine. Intraperitonial injection of IL-1β at varying doses (0-10μg) caused a concentration-dependent increase in mouse intestinal permeability to the paracellular marker dextran (10 KD), and the maximal increase in dextran flux occurred at IL-1β dose of 5μg. IL-1β treatment caused an increase in myosin light-chain kinase (MLCK) mRNA and protein expression in the small intestinal tissue starting at 24h, which continued up to 72h. Additionally, IL-1β did not cause an increase in intestinal permeability in MLCK-deficient mice (C57BL/6 MLCK-/-). MLCK inhibitor ML-7 (2mg/kg body weight) also inhibited the IL-1β-induced increase in small intestinal permeability. The IL-1β-induced increase in mouse intestinal permeability was associated with an increase in NF-κB activation. The intestinal tissue-specific silencing of NF-κB p65 inhibited the IL-1β-induced increase in intestinal permeability and increase in MLCK expression. These data show for the first time that IL-1β causes an increase in mouse intestinal permeability in vivo. These data suggested that the mechanism of IL-1β-induced increase in mouse intestinal permeability in vivo involved NF-κB p65-induced activation of the mouse enterocyte MLCK gene.

AB - Interleukin-1β (IL-1β) has been shown to play an essential role in mediating intestinal inflammation of Crohn's disease and other inflammatory conditions of the gut. Previous studies from our laboratory have shown that IL-1β causes an increase in intestinal tight-junction permeability in Caco-2 monolayers in vitro. However, the IL-1β effect on the intestinal epithelial barrier in vivo remains unclear. Aims: the major aims of this study were to examine the effect of IL-1β on mouse intestinal epithelial barrier in vivo and to delineate the mechanisms involved using an in vivo model system consisting of a recycling perfusion of mouse small intestine. Intraperitonial injection of IL-1β at varying doses (0-10μg) caused a concentration-dependent increase in mouse intestinal permeability to the paracellular marker dextran (10 KD), and the maximal increase in dextran flux occurred at IL-1β dose of 5μg. IL-1β treatment caused an increase in myosin light-chain kinase (MLCK) mRNA and protein expression in the small intestinal tissue starting at 24h, which continued up to 72h. Additionally, IL-1β did not cause an increase in intestinal permeability in MLCK-deficient mice (C57BL/6 MLCK-/-). MLCK inhibitor ML-7 (2mg/kg body weight) also inhibited the IL-1β-induced increase in small intestinal permeability. The IL-1β-induced increase in mouse intestinal permeability was associated with an increase in NF-κB activation. The intestinal tissue-specific silencing of NF-κB p65 inhibited the IL-1β-induced increase in intestinal permeability and increase in MLCK expression. These data show for the first time that IL-1β causes an increase in mouse intestinal permeability in vivo. These data suggested that the mechanism of IL-1β-induced increase in mouse intestinal permeability in vivo involved NF-κB p65-induced activation of the mouse enterocyte MLCK gene.

UR - http://www.scopus.com/inward/record.url?scp=84867505323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867505323&partnerID=8YFLogxK

U2 - 10.1089/jir.2012.0031

DO - 10.1089/jir.2012.0031

M3 - Article

C2 - 22817402

AN - SCOPUS:84867505323

VL - 32

SP - 474

EP - 484

JO - Journal of Interferon and Cytokine Research

JF - Journal of Interferon and Cytokine Research

SN - 1079-9907

IS - 10

ER -